
Fighting Infectious Disease
Our commitment to combatting infectious disease is significant and spans several disease states: most notably, HIV and TB.
In 2025, we provided access to high-quality and affordable ARVs to approximately 4.5 million patients across nearly 125 countries.
Since 2022, we have provided treatments for >28.1 million patients, including >1.8 million children. Today, approximately 45% of the world’s children receiving treatment for HIV use a Viatris product.
We are particularly proud of our contributions to combatting TB across the globe. Since 2019, we have provided TB screening for more than 1.5 million people in India. In the U.S., we provide lower-cost options for several common treatments in an effort to reduce the high cost of care. We also recently partnered with the TB Alliance to develop a treatment for multi-drug-resistant tuberculosis.

Delivering on Access to Primary Care in Africa
We are proud to have contributed financially to the establishment of two “Mpathy” primary care clinics to serve the people of Diepsloot, a growing township in South Africa.

Dispensary of Hope
Since 2012, Viatris has partnered with Dispensary of Hope, an organization that connects medication surplus from manufacturers and physicians with low-income and underinsured patients in the U.S. We have donated more than 338 million doses spanning 13 drug classes.







